Conference: EVER 2024

Conference

MiYOSMART

Myopia treatment

HOYA Initiated Studies

Defocus Incorporated Multiple Segments Lenses and 0.025% Atropine for Myopia Control in European Children: 12-Month Results of a Randomized Controlled Trial

Guemes Villahoz et al.

Vision-Related Quality of Life of Myopic Children Using Combination Treatment: Atropine and Defocus-Incorporated Multiple Segment Spectacle Lenses

Guemes Villahoz et al.

Prevalence of Amblyogenic Risk Factors Among Children Aged 3.5-5.5 Years in Scotland Who Fail Their Vision Screening

Conway et al.

Literature Review: Light and Colour in Myopia Control

Evans et al.

High Myopia: Reviews of Myopia Control Strategies and Myopia Complications

Vlasak et al.

Increasing Myopia Post-COVID: Evidence from Child Vision Screening Age 3.5 to 5.5 Years in Scotland

Evans et al.

Investigator Initiated Study

Performance Comparison of Peripheral Defocus Spectacle Lenses

Schiavetti et al.

Disclaimer: MiYOSMART spectacle lenses have not been approved for use in myopia management in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S